Mesenchymal stem cells ameliorate inflammation and pyroptosis in diabetic cardiomyopathy via the miRNA-223-3p/NLRP3 pathway.

ABSTRACT:

Background

Diabetic cardiomyopathy (DCM) stands as the primary cause of heart failure and mortality among patients with diabetes. Nevertheless, conventional treatment approaches are limited in their ability to effectively prevent myocardial tissue damage itself. Mesenchymal stem cell (MSC) therapy exhibits immense potential for treating DCM; however, the precise mechanisms involved in regulating inflammatory responses and pyroptosis processes, an emerging form of cellular death, within myocardial cells remain elusive. Hence, it is imperative to further elucidate the precise underlying mechanisms to facilitate the clinical implementation of MSC therapy.

Methods

In vivo, we established a DCM mouse model by administering streptozotocin and fed the mice a high-glucose and high-f

SUBMITTER: Yang Q 

PROVIDER: S-EPMC11221100 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature